Pemtrexed induced pneumonitis

Last revised by Yuranga Weerakkody on 27 Jan 2022

Citation, DOI, disclosures and article data

Citation:

Weerakkody Y, Sharma R, Luong D, et al. Pemtrexed induced pneumonitis. Reference article, Radiopaedia.org (Accessed on 25 Apr 2024) https://doi.org/10.53347/rID-83234

DOI:

https://doi.org/10.53347/rID-83234

Permalink:

https://radiopaedia.org/articles/83234

rID:

83234

Article created:

16 Oct 2020, Yuranga Weerakkody ◉

Disclosures:

At the time the article was created Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Last revised:

27 Jan 2022, Yuranga Weerakkody ◉

Disclosures:

At the time the article was last revised Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Revisions:

5 times, by 4 contributors - see full revision history and disclosures

Synonyms:

Pemtrexed induced lung injury
Pemtrexed related pneumonitis

Pemtrexed induced pneumonitis is a very rarely reported form of drug-induced lung disease occurring as a result of the drug pemtrexed (Alimta^TM) which is used in the treatment of malignant mesothelioma and non-small cell lung cancer (NSCLC).

Only limited literature has been published with most cases presenting as an acute pneumonitis (onset ranging between a few days to 4 weeks from dose) and reported to occur after 1-5 cycles ³. Variable outcomes have been reported.